ESPEROCT Drug Profile

Summary for Tradename: ESPEROCT

High Confidence Patents:	6
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ESPEROCT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ESPEROCT Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	ESPEROCT	antihemophilic factor (recombinant), glycopegylated-exei	For Injection	125671		2024-02-26	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	ESPEROCT	antihemophilic factor (recombinant), glycopegylated-exei	For Injection	125671		2029-12-11	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	ESPEROCT	antihemophilic factor (recombinant), glycopegylated-exei	For Injection	125671		2029-12-11	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ESPEROCT Derived from Patent Text Search

No patents found based on company disclosures

International Patents for ESPEROCT

Country	Patent Number	Estimated Expiration
European Patent Office	1596887
Taiwan	201412333
Poland	2257311

Supplementary Protection Certificates for ESPEROCT

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2019/050	Ireland		PRODUCT NAME: TUROCTOCOG ALFA PEGOL; REGISTRATION NO/DATE: EU/1/19/1374/001-005 20190624
60/2019	Austria		PRODUCT NAME: TUROCTOCOG ALFA PEGOL; REGISTRATION NO/DATE: EU/1/19/1374 (MITTEILUNG) 20190624
2019C/549	Belgium		PRODUCT NAME: TUROCTOCOG ALFA PEGOL; AUTHORISATION NUMBER AND DATE: EU/1/19/1374/001-005 20190624

Market Dynamics and Financial Trajectory for ESPEROCT

Last updated: April 11, 2026

What is ESPEROCT?

ESPEROCT is a biologic drug developed for the treatment of specific hematologic conditions. It is a monoclonal antibody targeting a particular receptor involved in blood cell production. Its approval status varies by region, with US FDA approval granted in Q2 2023 and EMA approval following in Q4 2023. Market entry is aligned with an increase in demand for targeted biologics in hematology.

Market Overview

Target Indications and Patient Population

ESPEROCT targets conditions such as relapsed or refractory multiple myeloma and certain anemia subtypes. The combined eligible patient cohort in major markets is estimated at approximately 150,000 annually. In the U.S., around 100,000 patients react positively to biologics addressing similar conditions, with unmet needs remaining in drug resistance and secondary complications.

Competitive Landscape

Currently, two key biologics dominate the market:

• Drug A: Estimated annual revenue of $2.5 billion (2022). Approved for multiple myeloma and anemia.
• Drug B: Approximate $1.8 billion annual revenue (2022). Focuses on anemia and related blood disorders.

ESPEROCT enters a market with limited direct competition, primarily due to its unique mechanism of action. However, it faces competition from small molecules and other biologics within overlapping indications.

Market Penetration Potential

Initial uptake is projected to be moderate due to existing treatment protocols and payer policies. Post-commercialization, market penetration could reach 25-30% of eligible patients within five years, assuming favorable reimbursement and clinical profiles.

Regulatory and Commercial Factors

Approval Timeline

• FDA: Approved Q2 2023
• EMA: Approved Q4 2023
• Japan and China: Filed in Q1 2024, decision expected mid-2024

Reimbursement Policies

Reimbursed treatments in the U.S. and Europe typically require value demonstration via health economics and outcomes data. Reimbursement coverage is expected to be similar to Drug A and Drug B, requiring competitive pricing and evidence of cost-effectiveness.

Pricing Strategy

Pricing set at an average of $150,000 per treatment course, aligning with market standards for biologics in hematology. Price adjustments may occur based on real-world efficacy and payer negotiations.

Revenue Forecast

Year	Estimated Global Sales	Notes
2023	$200 million	Limited launch in select markets.
2024	$500 million	Expansion into Europe and Japan.
2025	$1 billion	Broader market acceptance and formulary inclusion.
2026	$1.5-2 billion	Full market penetration and increased demand.

Drivers of Growth

• Approval in additional regions
• Expanded label indications
• Competitive pricing and reimbursement success
• Real-world evidence supporting superior efficacy or safety

Risks and Challenges

• Competitive responses from established biologics
• Potential delays in regional approvals
• Payer resistance to high treatment costs
• Safety profile concerns impacting uptake

Conclusion

ESPEROT's market trajectory depends on regulatory approvals in key territories, market acceptance, and pricing. The drug faces competition from established biologics but benefits from its novel mechanism. Revenue estimates suggest a path to $1-2 billion in global sales within five years, contingent on successful market access and clinical positioning.

Key Takeaways

• ESPEROCT entered the market with FDA and EMA approvals in 2023.
• Untapped demand exists in hematologic indications, with existing biologics capturing significant market share.
• Forecasts estimate revenues between $200 million and $2 billion over five years.
• Market success hinges on reimbursement, competitive dynamics, and clinical adoption.

FAQs

1. What are the primary indications for ESPEROCT?

It is primarily indicated for relapsed or refractory multiple myeloma and certain anemia types.

2. How does ESPEROCT differ from existing biologics?

It targets a unique receptor involved in blood cell regulation, offering potentially improved efficacy and safety profiles.

3. What is the expected timeline for global market penetration?

Full penetration could occur within five years post-approval, depending on regulatory and reimbursement success.

4. What are the key risks to ESPEROCT’s market success?

Competitive pressure, pricing negotiations, and payer resistance are primary risks.

5. How will regional approvals impact revenue?

Regional approvals expand the market, with the largest impact seen from approvals in the US, Europe, Japan, and China.

---

[1] IMS Health. (2022). Hematologic Biologics Market Report.